Open AccessTrans ε viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model
Author(s) -
Martial Caillaud,
Jérôme Guillard,
Damien Richard,
Serge Milin,
Damien Chassaing,
Marc Pocard,
Guylène Page,
Agnès Rioux Bilan
Publication year - 2019
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0212663
Subject(s) - microglia , genetically modified mouse , transgene , inflammation , alzheimer's disease , amyloid (mycology) , intraperitoneal injection , microbiology and biotechnology , chemistry , biology , pharmacology , pathology , immunology , medicine , disease , biochemistry , gene
As Alzheimer’s disease (AD) induces several cellular and molecular damages, it could be interesting to use multi-target molecules for therapeutics. We previously published that trans ε -viniferin induced the disaggregation of Aβ 42 peptide and inhibited the inflammatory response in primary cellular model of AD. Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that trans ε -viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.